After disappointing trial, Editas puts lead CRISPR drug on hold
CRISPR/Cas9, Editas, gene editing, inherited disease, ophthalmology
0 Comment
gene editing
Vertex, CRISPR prep filing for gene-editing blood disorder therapy
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex
0 Comment
Verve starts trials of cholesterol drug in test of base editing technique
cholesterol, CRISPR/Cas9, gene editing, heterozygous familial hypercholesterolaemia, Leqvio, PCSK9, Praluent, Repatha, Verve Therapeutics
0 Comment
Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis
beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease
0 Comment
EHA: Vertex, CRISPR build case for gene-editing drug
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, EHA 2022, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Stem cell therapy ‘cures’ first woman with HIV, say researchers
gene editing, HIV, infectious disease, stem cell therapy
0 Comment
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering
0 Comment
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
